Biosimilar Development Editorial Board

Source: Biosimilar Development

Fouad Atouf, Vice President, Science—Global Biologics, U.S. Pharmacopeia

Hillel Cohen,
Executive Director,
Scientific Affairs,

Ross Day, Consulting Hospital Pharmacist, Former Director of Pharmacy, Vizient

Colin C. Edgerton, MD FACP FACR, Executive Chairman, American Rheumatology Network

Edric Engert, Managing Director, Abraxeolus Consulting

Tiffany Fletcher, Head of Global Biosimilar Policy & Access, International Affairs & Global Policy, Viatris

Francois-Xavier Frapaise, M.D., ClinExcel

Matthew Harman, PharmD, MPH, Director of Pharmacy, Employers Health

HoUng Kim,
Head of The Medical and Marketing Division,
Celltrion Healthcare

Kevin Knopf,
Division Chief, Hematology/Oncology,
Alameda Health Systems Oakland, California

Brian Lehman, MBA, MHA, RPh., Director, Strategic Alliances & Patient Advocacy, Sandoz

Julie Maréchal-Jamil, Director Biosimilars Policy & Science,
Medicines for Europe

Sean McGowan, Senior Director Biosimilars,

Sonia T. Oskouei, PharmD, BCMAS, DPLA Vice President, Biosimilars
Cardinal Health

Kathy W. Oubre, MS, Chief Operations Officer
Pontchartrain Cancer Center

Ned Pojskic, Leader, Pharmacy & Health Provider Relations
Green Shield Canada

Juliana M. Reed, Vice President, Corporate Affairs Lead – I & I and Biosimilars
Pfizer, Inc.

Sundar Ramanan, Vice President & Head, Global Regulatory Affairs,
Biocon Biologics

Jenny Shmuel, Principal, Fish & Richardson P.C.

Noelle Sunstrom, CEO, NeuClone

Alexandra Valenti, Partner, Goodwin Procter LLP

Lauren Vela, Senior Director, Pacific Business Group on Health

Gillian Woollett, Senior Vice President, Avalere Health